PRTC's Gallop Presents Ph1b LYT-200 Data at ESMO

LYT-200 shows promising Phase 1b results, but Phase 2 depends on new funding.

What the company is saying

PureTech Health plc, through its entity Gallop Oncology, is highlighting positive Phase 1b data for LYT-200 in relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML), presented at ESMO 2026 in Madrid. The company emphasizes LYT-200’s 36.4% complete/partial response rate and 45.5% overall response rate in a heavily pretreated HR-MDS cohort, with two patients achieving MRD-negative complete responses leading to stem cell transplantation. Safety is a central message: across 101 patients, there were no dose-limiting toxicities, serious adverse events, or deaths attributed to LYT-200, and no additive toxicities in combination regimens. The announcement stresses the mutation-agnostic potential of LYT-200 and the significant unmet need, noting that only one FDA-approved therapy exists for R/R HR-MDS, targeting just 3% of patients. Guenther Koehne, MD, PhD, a recognized clinical leader, is quoted to reinforce clinical credibility. The company frames the next step as advancing to a randomized Phase 2 trial (STRIDE-MDS) after receiving FDA Fast Track designation, but makes clear this is contingent on securing external capital.

What the data suggests

The Phase 1b trial enrolled 101 heavily pretreated patients with R/R HR-MDS or AML across nine U.S. sites, with efficacy-evaluable HR-MDS patients (n=11) showing a 36.4% complete/partial response rate and a 45.5% overall response rate when treated with LYT-200 at 12 mg/kg plus a hypomethylating agent. All patients in this cohort had previously received HMA therapy, had a median of 3 prior lines of therapy, and had high-risk cytogenetics, indicating a difficult-to-treat population. Two patients achieved MRD-negative complete responses and underwent stem cell transplantation. Safety data are robust: no dose-limiting toxicities, infusion reactions, dose reductions, or LYT-200-related serious adverse events, discontinuations, or deaths were reported in the 101-patient safety population. No additive toxicities occurred in combination regimens. The company plans a Phase 2 trial (STRIDE-MDS) with 125 patients, randomized 2:2:1 across two LYT-200 doses and placebo, but this is not yet initiated and is dependent on external funding. The addressable U.S. MDS population is estimated at 60,000–170,000, with 30–40% classified as high-risk; only about 3% of R/R HR-MDS patients are eligible for the single currently approved therapy. No financial figures, cash position, or operational revenue are disclosed.

Analysis

The announcement presents detailed and credible Phase 1b clinical data for LYT-200, including specific response rates and safety outcomes in a heavily pretreated HR-MDS population. These realised results are well-supported by numerical evidence and are not overstated. However, the tone shifts to a more aspirational narrative when discussing the planned Phase 2 STRIDE-MDS trial, which is contingent on securing external capital and has not yet commenced. The benefits of the program (potential regulatory approval, commercialisation) are therefore long-term and uncertain. The need for external funding before the next phase introduces execution risk and delays any tangible value creation. While the clinical progress is genuine, the announcement's positive framing of future plans and regulatory milestones (e.g., Fast Track designation) may inflate investor expectations relative to the actual stage of development and the hurdles remaining.

Risk flags

• ●The planned Phase 2 STRIDE-MDS trial cannot begin until Gallop Oncology secures external capital, introducing significant financing risk and potential delays to development. Without new funding, clinical progress will stall.
• ●All efficacy and safety data are from a small Phase 1b cohort (n=11 for efficacy in HR-MDS), limiting statistical power and generalizability. Larger, randomized trials are needed to confirm benefit.
• ●The target patient population is heavily pretreated and high-risk, which increases the challenge of demonstrating meaningful clinical benefit in future studies and may complicate regulatory approval.
• ●The only FDA-approved therapy for R/R HR-MDS targets a mutation found in just 3% of patients, highlighting the unmet need but also the lack of precedent for broad regulatory success in this indication.
• ●No financial data, cash runway, or fundraising plans are disclosed, making it difficult to assess the company’s ability to support ongoing development or withstand delays.

Bottom line

PureTech Health’s Phase 1b results for LYT-200 in relapsed/refractory HR-MDS and AML show encouraging response rates and a clean safety profile in a difficult patient population, with two patients achieving MRD-negative complete responses and proceeding to stem cell transplant. The clinical data are credible but drawn from a small cohort, and the next step—a randomized Phase 2 trial—remains aspirational until external funding is secured. The company’s narrative is well-supported by the disclosed figures, but the lack of financial disclosure and the explicit need for new capital introduce material execution risk. The addressable market is large, with 60,000–170,000 U.S. MDS patients and a significant unmet need, but timelines to value are long and contingent on successful fundraising and trial execution. Investors should focus on whether Gallop Oncology can raise the necessary capital and initiate the Phase 2 trial; until then, the program’s future remains uncertain. The most important takeaway is that while the science is promising, the next inflection point depends entirely on financing.

Announcement summary

(LSE:PRTC) PureTech Health plc announced that results from the Phase 1b clinical trial of LYT-200 were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. LYT-200 is a first-in-class monoclonal antibody targeting galectin-9 and is being advanced by PureTech's Founded Entity, Gallop Oncology. The completed Phase 1b trial (NCT05829226) was conducted across nine U.S. sites and evaluated LYT-200 as both monotherapy and in combination regimens in 101 heavily pretreated patients with relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS) or acute myeloid leukemia (AML). In R/R HR-MDS, LYT-200 at 12 mg/kg in combination with a hypomethylating agent (HMA) demonstrated a 36.4% complete response plus partial response rate and a 45.5% overall response rate in 11 efficacy-evaluable patients, all of whom had previously received HMA therapy. Two patients in this cohort achieved MRD-negative complete responses and subsequently proceeded to stem cell transplantation. Efficacy-evaluable R/R HR-MDS patients had a median of 3 prior lines of therapy (range: 1-5), and all (100%) had previously been treated with an HMA. Clinical responses were observed across patients with a range of mutations, and all patients had high-risk cytogenetics. LYT-200 demonstrated a favorable and consistent safety profile across all cohorts and dose levels studied (N=101), with no dose-limiting toxicities, infusion-related reactions, LYT-200 dose reductions, or LYT-200-related serious adverse events, discontinuations, or deaths. No overlapping or additive toxicities were observed when LYT-200 was combined with an HMA or venetoclax/HMA. Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Baptist Health Herbert Wertheim Cancer Institute, presented the Phase 1b results at ESMO and commented on the combination of clinical activity, depth of response, and tolerability observed in patients who have already received multiple lines of treatment. Following a successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) and receipt of Fast Track designation for R/R HR-MDS, Gallop Oncology plans to advance LYT-200 into Phase 2 development. The STRIDE-MDS trial will be a randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 125 patients with R/R HR-MDS. Patients will be randomized 2:2:1 to receive LYT-200 at 12 mg/kg plus an HMA, LYT-200 at 7.5 mg/kg plus an HMA, or placebo plus an HMA. The trial will assess the efficacy of LYT-200 as measured by the rate of complete and partial responses to support dose selection. Gallop plans to initiate the trial after securing external capital. Myelodysplastic syndromes (MDS) affect approximately 60,000-170,000 people in the United States, with an estimated 30-40% of patients diagnosed with the more aggressive form known as high-risk (HR) MDS. Only one therapy has been approved by the U.S. FDA specifically for R/R HR-MDS in the past two decades, and it targets a genetic mutation found in only approximately 3% of patients. LYT-200 has been granted Fast Track designation from the U.S. FDA for the treatment of R/R HR-MDS in combination with a hypomethylating agent and for the treatment of AML. Gallop Oncology is wholly owned by PureTech Health plc.

Disagree with this article?